Comparing Revenue Performance: Pfizer Inc. or Dynavax Technologies Corporation?

Pfizer vs. Dynavax: A Decade of Revenue Dynamics

__timestampDynavax Technologies CorporationPfizer Inc.
Wednesday, January 1, 20141103200049605000000
Thursday, January 1, 2015405000048851000000
Friday, January 1, 20161104300052824000000
Sunday, January 1, 201732700052546000000
Monday, January 1, 2018819800053647000000
Tuesday, January 1, 20193521900051750000000
Wednesday, January 1, 20204655100041908000000
Friday, January 1, 202143944200081288000000
Saturday, January 1, 2022722683000100330000000
Sunday, January 1, 202323228400058496000000
Monday, January 1, 202463627000000
Loading chart...

Unleashing insights

A Tale of Two Companies: Pfizer Inc. vs. Dynavax Technologies Corporation

In the ever-evolving pharmaceutical industry, revenue performance is a key indicator of a company's market position and growth potential. Over the past decade, Pfizer Inc. has consistently demonstrated its dominance, with revenues peaking at over $100 billion in 2022, a staggering 1,000% higher than Dynavax Technologies Corporation's highest revenue in the same year. Despite Dynavax's impressive growth, particularly in 2021 and 2022, where revenues surged by over 1,000% compared to 2020, it remains a smaller player compared to Pfizer. This comparison highlights the vast scale and reach of Pfizer, a global pharmaceutical giant, while showcasing Dynavax's potential for growth in niche markets. As the industry continues to innovate, these revenue trends offer a glimpse into the strategic directions and market dynamics shaping the future of pharmaceuticals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025